v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2017
Jun. 30, 2016
Current assets:    
Cash $ 12,422 $ 23,014
Accounts receivable - trade 128 484
Accounts receivable - unbilled 0 122
Work in process 60 22
Prepaid expenses and other current assets 374 264
Total current assets 12,984 23,906
Fixed assets, net of accumulated depreciation 25,794 25,574
Intangible assets, net of accumulated amortization 1,895 2,092
Security deposit 25 28
Total Assets 40,698 51,600
Current liabilities:    
Accounts payable (related party of $199 and $200 as of March 31, 2017 and June 30, 2016, respectively) 1,391 1,177
Accrued expenses (related party of $784 and $623 as of March 31, 2017 and June 30, 2016, respectively) 957 920
Capital lease obligation - current portion 180 170
Deferred revenue 93 24
Total Current Liabilities 2,621 2,291
Capital lease obligation - net of current portion 25,129 25,265
Total Liabilities 27,750 27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - $0.001 value; 1,000,000 shares authorized; 1 and 0 shares issued and outstanding as of March 31, 2017 and June 30, 2016, respectively 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,118,510 and 89,109,410 shares issued and outstanding as of March 31, 2017 and June 30, 2016, respectively 89 89
Additional paid-in capital 80,680 67,468
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (67,794) (57,591)
Total iBio, Inc. Stockholders’ Equity 12,946 9,937
Noncontrolling interest 2 14,107
Total Equity 12,948 24,044
Total Liabilities and Equity $ 40,698 $ 51,600

Source

v3.7.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Revenues $ 37 $ 379 $ 247 $ 673
Operating expenses:        
Research and development (related party of $225, $244, $670 and $723), net of grant income of ($44, $7, $84 and $7) 1,136 1,048 3,005 2,303
General and administrative (related party of $191, $303, $553 and $395) 2,837 2,403 7,657 5,509
Total operating expenses 3,973 3,451 10,662 7,812
Operating loss (3,936) (3,072) (10,415) (7,139)
Other income (expense):        
Interest expense (related party of $481, $323, $1,447 and $323) (481) (323) (1,447) (323)
Interest income 8 5 33 9
Royalty income 4 5 20 17
Total other income (expense) (469) (313) (1,394) (297)
Consolidated net loss (4,405) (3,385) (11,809) (7,436)
Net loss attributable to noncontrolling interest 492 349 1,606 349
Net loss attributable to iBio, Inc. (3,913) (3,036) (10,203) (7,087)
Preferred stock dividends (26) 0 (26) 0
Net loss available to iBio, Inc. (3,939) (3,036) (10,229) (7,087)
Comprehensive loss:        
Consolidated net loss (4,405) (3,385) (11,809) (7,436)
Other comprehensive income (loss) - foreign currency translation adjustments 0 2 0 (6)
Comprehensive loss $ (4,405) $ (3,383) $ (11,809) $ (7,442)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.04) $ (0.11) $ (0.09)
Weighted-average common shares outstanding - basic and diluted 89,109 81,158 89,109 78,587

Source

v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash flows from operating activities:    
Consolidated net loss $ (11,809) $ (7,436)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 713 940
Amortization of intangible assets 264 274
Depreciation 987 263
Loss on abandonment of intangible assets 0 33
Changes in operating assets and liabilities    
Accounts receivable - trade 357 (9)
Accounts receivable - unbilled 122 0
Work in process (38) (58)
Prepaid expenses and other current assets (110) (136)
Security deposit 3 (28)
Accounts payable 7 342
Accrued expenses 37 489
Deferred revenue 69 76
Net cash used in operating activities (9,398) (5,250)
Cash flows from investing activities:    
Additions to intangible assets (259) 0
Purchases of fixed assets (809) (8)
Net cash used in investing activities (1,068) (8)
Cash flows from financing activities:    
Proceeds from sale of common stock 0 2,178
Proceeds from exercise of warrants 0 1,009
Capital contribution - noncontrolling interest 0 15,000
Payment of capital lease obligation (126) (525)
Net cash (used in) provided by financing activities (126) 17,662
Effect of exchange rate changes 0 (5)
Net (decrease) increase in cash (10,592) 12,399
Cash - beginning of period 23,014 9,494
Cash - end of period 12,422 21,893
Schedule of non-cash activities:    
Issuance of preferred stock for acquisition of additional interest in subsidiary 12,499 0
Unpaid intangible assets included in accounts payable 197 87
Fixed assets included in accounts payable in FY 2016, paid in FY 2017 71 0
Unpaid fixed assets included in accounts payable 468 17
Purchases of fixed assets financed by capital lease 0 26,000
Supplemental cash flow information:    
Cash paid during the period for interest $ 1,449 $ 0

Source